Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest
Display:
?
Drug:  HDAC6 inhibitor ACY-1215
Find trials that include:  Any drugs shown
Results 1-5 of 5 for your search:
Start Over
Study of ACY-1215 Alone and in Combination With Bortezomib and Dexamethasone in Multiple Myeloma
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: ACY-100, NCI-2011-03019, NCT01323751
ACY-1215 (Ricolinostat) in Combination With Pomalidomide and Low-dose Dex in Relapsed-and-Refractory Multiple Myeloma
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: ACE-MM-102, NCI-2014-00978, NCT01997840
HDAC6 Inhibitor ACY-1215 in Treating Patients with Relapsed or Refractory Non-Hodgkin Lymphoma or Hodgkin Lymphoma
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: AAAM4054, NCI-2014-01521, IRB-AAAM4054, NCT02091063
Study of ACY-1215 in Combination With Lenalidomide, and Dexamethasone in Multiple Myeloma
Phase: Phase I
Type: Treatment
Age: 18 and over
Trial IDs: ACE-MM-101, NCI-2012-01280, NCT01583283
Phase 1b Study Evaluating ACY-1215 (Ricolinostat) in Combination With Pomalidomide and Dexamethasone in Relapsed or Relapsed-and-Refractory Multiple Myeloma
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: ACE-MM-104, NCI-2014-01879, NCT02189343
Start Over